Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203164 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
A Phase 3 study of Parkinson's Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 254
- Enrollment target
- 6
- Study locations
NCT00203164 is a Phase 3 study of Parkinson's Disease that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 254 participants, below the 641-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (60% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT00203164, a Phase 3 study of Parkinson's Disease, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 254 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a study to look at the effectiveness, tolerability, and safety of one dose of rasagiline in advanced Parkinson's disease (PD) patients who have been treated with Levodopa/Carbidopa therapy.
Conditions Studied
Interventions
- DRUG rasagiline mesylate
Study Locations (6)
New York
- Long Island Jewish Medical Center - New Hyde Park
- University of Rochester - Rochester
California
- Margolin Brain Institute - Fresno
Illinois
- Rush - Presbyterian St. Luke's Medical Center - Chicago
Nebraska
- Creighton University - Omaha
Pennsylvania
- Pennsylvania Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2002-05 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203164
The ClinicalTrials.gov registry entry for NCT00203164 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 641-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (60% lower). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which rasagiline mesylate is the first listed.
NCT00203164 reports 6 study locations spanning 5 distinct geographic areas - top geographies include New York, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00203164 about?
NCT00203164 is a clinical study titled "Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients". This is a study to look at the effectiveness, tolerability, and safety of one dose of rasagiline in advanced Parkinson's disease (PD) patients who have been treated with Levodopa/Carbidopa therapy.
What is the current status of trial NCT00203164?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 254 participants. The study started on 2002-05. Estimated completion is 2006-09.
What conditions does trial NCT00203164 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00203164?
The interventions under investigation include: rasagiline mesylate (DRUG).
Who is sponsoring clinical trial NCT00203164?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00203164 being conducted?
This trial has 6 study locations across California, Illinois, Nebraska, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
RECRUITING · Phase 3
-
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
ACTIVE NOT RECRUITING · Phase 3
-
Deep Brain Stimulation for Parkinson's Disease Trial
COMPLETED · Phase 3
-
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
COMPLETED · Phase 3
-
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.